The global generic drug industry is poised for a big shakeup with Pfizer Inc. and Mylan NV announcing plans for Mylan to merge with Pfizer's Upjohn off-patent branded and generic medicines business, establishing the top generic drug company in the world based on consolidated revenues. The companies announced the merger on 29 July, a deal that will combine two slow-growing businesses in the challenging generic drug market.
The combination will result in a new company with expected 2020 pro forma revenues of $19bn to $20bn, edging out...








